Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.
Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.
Eli Lilly (NYSE: LLY) dominates the weight loss market, but fierce competition is on the horizon with several anti-obesity medicine launches in the pipeline. One potential challenger is Viking Therapeutics (NASDAQ: VKTX), a drugmaker that recently presented impressive clinical results from a trial of its lead candidate. The study involved around 180 patients who were given either a dose of VK2735 or a placebo.
Starting with weekly administration, patients on the drug lost between 16% and 19% of their body weight after 21 weeks. Following this initial phase, participants transitioned to maintenance regimens, taking VK2735 every other week or monthly for an additional 12 weeks.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
